BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gastelurrutia P, Prat-Vidal C, Vives J, Coll R, Bayes-Genis A, Gálvez-Montón C. Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience. Front Cardiovasc Med 2021;8:604434. [PMID: 33614746 DOI: 10.3389/fcvm.2021.604434] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Aguilera-cobos L, Rosario-lozano MP, Ponce-polo A, Blasco-amaro JA, Epstein D. Barriers for the evaluation of advanced therapy medicines and their translation to clinical practice: Umbrella review. Health Policy 2022. [DOI: 10.1016/j.healthpol.2022.10.007] [Reference Citation Analysis]
2 Vives J, Hernández J, Mirabel C, Puigdomenech-Poch M, Romeo-Guitart D, Marmolejo-Martínez-Artesero S, Cabrera-Pérez R, Jaramillo J, Kumru H, García-López J, Vidal-Samsó J, Navarro X, Coll-Bonet R. Preclinical Development of a Therapy for Chronic Traumatic Spinal Cord Injury in Rats Using Human Wharton's Jelly Mesenchymal Stromal Cells: Proof of Concept and Regulatory Compliance. Cells 2022;11:2153. [PMID: 35883596 DOI: 10.3390/cells11142153] [Reference Citation Analysis]
3 Muñoz-Domínguez N, Roura S, Prat-Vidal C, Vives J. Wharton's Jelly Mesenchymal Stromal Cells and Derived Extracellular Vesicles as Post-Myocardial Infarction Therapeutic Toolkit: An Experienced View. Pharmaceutics 2021;13:1336. [PMID: 34575412 DOI: 10.3390/pharmaceutics13091336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 García-Muñoz E, Vives J. Towards the standardization of methods of tissue processing for the isolation of mesenchymal stromal cells for clinical use. Cytotechnology 2021;:1-10. [PMID: 33994662 DOI: 10.1007/s10616-021-00474-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]